NCT07494942Recruiting
Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if a structured cardiac rehabilitation program can help people with cardiac amyloidosis improve their ability to exercise and their quality of life. The main questions it aims to answer are: Does cardiac rehabilitation raise peak oxygen uptake (VO₂ peak), which shows how well the heart and lungs work during exercise? Is cardiac rehabilitation safe and practical for people with cardiac amyloidosis? How does cardiac rehabilitation affect other exercise measures, heart function, symptoms linked to autonomic dysfunction, and quality of life? This study has no comparison group. Researchers will measure each participant's results before and after the rehabilitation program. Participants will: Complete a cardiac rehabilitation program for 5 weeks. Have tests before the program starts and again about 3 months later. These tests include: A cardiopulmonary exercise test A heart function test using electrical impedance A questionnaire about quality of life A blood sample A blood pressure test to check for orthostatic hypotension The study will include adults aged 18 or older with transthyretin cardiac amyloidosis who are able to perform an exercise test.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 19 Mar 2026
- Start date
- 23 Sept 2026
- Primary completion date
- 23 Sept 2029
- Lead sponsor
- University Hospital, Montpellier
- Diseases
- Amyloidosis, Heart failure
- NCT number
- NCT07494942
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 23 Sept 2026 to the primary completion date, 23 Sept 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Uncontrolled ventricular arrhythmias
- NYHA Class IV heart failure
Other
- Inability to give informed consent to participate in the study
- Inability to monitor the patient during the study period
- Subject not enrolled in a social security program or not eligible for such a program
- Pregnant or breastfeeding women, patients unable to give consent, protected adults, vulnerable persons
- Subjects deprived of liberty by judicial or administrative decision
Who the study is looking for
- Age 18 or older
- Cardiac ATTR amyloidosis diagnosed according to guidelines: Perugini grade II or III uptake on bone scintigraphy, without monoclonal gammopathy.
- Ability to undergo a stress test
- Available to complete the 5-week rehabilitation program within 30 days of the stress test
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| KRIEF Coordinator of this site? Confirm its status | Montpellier | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.